Last week, our client Breye Therapeutics announced the appointment of Dr Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors. It also launched its new website and LinkedIn page. Breye is a clinical-stage biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of […]
Stress urinary incontinence (SUI) is a common and debilitating problem for many women, particularly after childbirth or in later years. Yet despite this treatment options are limited, held back by a lack of research into medical products focused on women’s health. But one biotech, Versameb, hopes to change this with a novel mRNA therapy that […]
On the 4 April 2023, Adcendo announced the extension of its Series A financing to ensure broad development of its first-in-class ADC pipeline. The financing was led by Pontifax Venture Capital with participation by existing investors Novo Holdings and Ysios Capital which together raised an additional EUR 31M taking its total funds to EUR 82M. The funding from the strong and committed syndicate of […]
Following Jeremy Hunt’s 2023 budget delivered earlier this month, in which he paved the way for faster access to new drugs and revealed R&D tax credits for life sciences companies, Bloomberg looked at the many challenges still facing the UK’s life sciences sector. Despite the success of the Oxford Covid-19 vaccine, the UK is still […]
Emerging new Company veriNOS pharmaceuticals, established in October 2022, Led by CEO, Christian Wandersee and CMO Professor John Stover, provides an update on its revival of late-stage drug candidate ronopterin for the treatment of Traumatic Brain Injury (TBI). Ronopterin is the first and only iNOS inhibitor which has demonstrated repeated signs of neuroprotection in TBI […]
